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The Authors’ reply We appreciate
Dr West’s comments on our paper1; he has
given us the opportunity to clarify some
points that seem unresolved.
First, we conﬁrm that the analysis was
conducted as intention-to-treat. We fully
agree with Dr West that a lower rate of
in-hospital death in the staged revascularisa-
tion (SR) compared with the culprit only
revascularisation (COR) group is surprising.
However, the study was not powered to
address in-hospital mortality, rather the main
study endpoint was a composite of all major
adverse cardiac events (MACE) including
cardiac and non-cardiac death, in-hospital
death, re-infarction, re-hospitalisation for
acute coronary syndrome and repeat
unplanned coronary revascularisation. Thus,
the imbalance of the in-hospital death rate
between these twogroupsmaybe the result of
an underpowered population for these events.
Furthermore, we observed an unexpected
lower percentage of patients treated with
clopidogrel in the COR group (92%) than in
the SR group (100%) that approached statis-
tical signiﬁcance. Thismay have increased the
rate of in-hospital coronary complications (eg,
stent thrombosis or re-infarction evolving to
death) in the group randomised to COR.
Secondly, we used the MACE rates of the
study of Qarawani et al2 for sample size
calculation because despite its non-rando-
mised design, this was the most recently
published study on the topic and enrolled
patients in a recent era, thus providing
results comparable with ours. In contrast,
the study by Di Mario et al3 was published in
2004 and the enrolment stopped well before
2003dthat is, before the beginning of our
study. Indeed, one of the strengths of our
trial is that, given the relatively recent
enrolment time, all percutaneous coronary
interventions (PCIs) were performed using
contemporary devices and treatments, thus
providing an up-to-date picture of the current
practice in ST-elevation myocardial infarction
(STEMI). Furthermore, the study by Ijssel-
muiden et al4 was based on a randomised
strategy but it excluded patients having PCI
during acute myocardial infarction; therefore,
this population is totally non-comparable
with our study population of STEMI patients
undergoing primary PCI.
Finally, we agree with the author that this
is a very controversial ﬁeld and that further
larger multicentre trials are needed before
there is enough evidence to change the
current guidelines.
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CT or MRI for post-procedural
aortic stenting?
To the Editor We thank Drs Rosenthal and
Bell for their insightful editorial comments1
relating to our study.2 There is little doubt
that until we have longer follow-up on the
incidence of potential adverse events
following coarctation stenting, some form of
advanced imaging is required, and this is
endorsed by ongoing large follow-up
studies.3 Although we agree that with
speciﬁc imaging techniques MRI may
provide information regarding complications
particularly in newer platinum stents, there
are numerous reports demonstrating almost
complete loss of signal with stainless steel
stents when imaging with MRI.4 Although
the authors have demonstrated a case in
which protrusion of the aortic wall is seen
with MRI following a stainless steel stent,
smaller aneurysms have been missed (A.
Taylor, personal communication). In many
countries including the USA, platinum
stents are not available and stainless steel
stents are used almost exclusively. MRI, as
the authors point out, is less available than
CT and this has implications for patient
follow-up, requiring patients to travel to
a specialised centre for imaging, and this has
had implications on patient compliance in
our region. As the authors also point out,
MRI will not detect stent fractures; however,
it is not true that it is only the complications
of these that require intervention. It is our
practice to re-stent in the setting of
a circumferential stent fracture and this may
be missed with MRI. Also, the ability of MRI
to demonstrate increased ﬂow velocity distal
to the stent is very dependent on where the
restenosis occurs within the stent and where
the velocity sample is acquired below the
stent. CT offers excellent in-stent imaging,
allowing preprocedural planning of further
intervention and limiting unnecessary cath-
eter procedures. It is beyond argument that
MRI offers more functional data on left
ventricular dynamics; however, this requires
time and cost and is not usually indicated in
the setting of speciﬁc post-stent follow-up
imaging. We fully accept the radiation doses
associated with CT and the authors are
correct to point out that this dose is cumu-
lative; however, the ultimate goal of
a screening tool should be to provide sensi-
tive and speciﬁc data to guide further
management. MRI may provide this in
selected cases, but it is questionable whether
it will do so over the general population and
over the range of stents used in coarctation
of the aorta, and thus we continue to
advocate the use of CT with continued
efforts to minimise radiation doses.
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